O_老虎社区_美港股上老虎

WilliamFish
2022-02-04

Bristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line<blockquote>百时美施贵宝非 GAAP 每股收益为 1.83 美元，超过预期为 0.03 美元，收入为 12B 美元</blockquote>

Bristol Myers Squibbpress release(NYSE:BMY): Q4 Non-GAAP EPS of $1.83beats by $0.03.Revenue of $12B

Bristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line<blockquote>百时美施贵宝非 GAAP 每股收益为 1.83 美元，超过预期为 0.03 美元，收入为 12B 美元</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":633690400,"tweetId":"633690400","gmtCreate":1643979047092,"gmtModify":1643979047266,"author":{"id":3584440700668924,"idStr":"3584440700668924","authorId":3584440700668924,"authorIdStr":"3584440700668924","name":"WilliamFish","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>O</p></body></html>","htmlText":"<html><head></head><body><p>O</p></body></html>","text":"O","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/633690400","repostId":1103110781,"repostType":4,"repost":{"id":"1103110781","kind":"news","pubTimestamp":1643976351,"share":"https://www.laohunote.com/m/news/1103110781?lang=zh_CN&edition=full","pubTime":"2022-02-04 20:05","market":"us","language":"en","title":"Bristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line<blockquote>百时美施贵宝非 GAAP 每股收益为 1.83 美元，超过预期为 0.03 美元，收入为 12B 美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1103110781","media":"Seeking Alpha","summary":"Bristol Myers Squibbpress release(NYSE:BMY): Q4 Non-GAAP EPS of $1.83beats by $0.03.Revenue of $12B ","content":"<p><html><head></head><body><ul><li>Bristol Myers Squibbpress release(NYSE:BMY): Q4 Non-GAAP EPS of $1.83beats by $0.03.</li><li>Revenue of $12B (+8.1% Y/Y) in-line.</li><li><b>Revenue breakdown:</b>Eliquis of $2.67B vs. $2.41B in 3Q21; Opdivo of $1.99B vs. $1.91B in 3Q21; Revlimid of $3.33B vs. $3.35B in 3Q21.</li><li>Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022</li><li>Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95</li></ul></body></html></p><p><blockquote><html><head></head><body><ul><li>百时美施贵宝新闻稿（纽约证券交易所股票代码：BMY）：第四季度非 GAAP 每股收益为 1.83 美元，超出 0.03 美元。</li><li>收入为 $12B（同比增长 8.1%）。</li><li><b>收入明细：</b>Eliquis 为 $2.67B，而2021年第三季度为 $2.41B；Opdivo 为 $199B，而2021年第三季度为 $191B；Revlimid 为 $3.33B，而2021年第三季度为 $3.35B。</li><li>宣布150亿美元股票回购授权；50亿美元加速股票回购协议将于2022年第一季度执行</li><li>百时美施贵宝推出 2022 年 GAAP 每股收益指导范围为 3.37 美元 - 3.67 美元，并重申其非 GAAP 每股收益指导范围为 7.65 美元 - 7.95 美元</li></ul></body></html></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line<blockquote>百时美施贵宝非 GAAP 每股收益为 1.83 美元，超过预期为 0.03 美元，收入为 12B 美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line<blockquote>百时美施贵宝非 GAAP 每股收益为 1.83 美元，超过预期为 0.03 美元，收入为 12B 美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-02-04 20:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><ul><li>Bristol Myers Squibbpress release(NYSE:BMY): Q4 Non-GAAP EPS of $1.83beats by $0.03.</li><li>Revenue of $12B (+8.1% Y/Y) in-line.</li><li><b>Revenue breakdown:</b>Eliquis of $2.67B vs. $2.41B in 3Q21; Opdivo of $1.99B vs. $1.91B in 3Q21; Revlimid of $3.33B vs. $3.35B in 3Q21.</li><li>Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022</li><li>Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95</li></ul></body></html></p><p><blockquote><html><head></head><body><ul><li>百时美施贵宝新闻稿（纽约证券交易所股票代码：BMY）：第四季度非 GAAP 每股收益为 1.83 美元，超出 0.03 美元。</li><li>收入为 $12B（同比增长 8.1%）。</li><li><b>收入明细：</b>Eliquis 为 $2.67B，而2021年第三季度为 $2.41B；Opdivo 为 $199B，而2021年第三季度为 $191B；Revlimid 为 $3.33B，而2021年第三季度为 $3.35B。</li><li>宣布150亿美元股票回购授权；50亿美元加速股票回购协议将于2022年第一季度执行</li><li>百时美施贵宝推出 2022 年 GAAP 每股收益指导范围为 3.37 美元 - 3.67 美元，并重申其非 GAAP 每股收益指导范围为 7.65 美元 - 7.95 美元</li></ul></body></html></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3795965-bristol-myers-squibb-non-gaap-eps-of-1_83-beats-0_03-revenue-of-12b-in-line\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3795965-bristol-myers-squibb-non-gaap-eps-of-1_83-beats-0_03-revenue-of-12b-in-line","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103110781","content_text":"Bristol Myers Squibbpress release(NYSE:BMY): Q4 Non-GAAP EPS of $1.83beats by $0.03.Revenue of $12B (+8.1% Y/Y) in-line.Revenue breakdown:Eliquis of $2.67B vs. $2.41B in 3Q21; Opdivo of $1.99B vs. $1.91B in 3Q21; Revlimid of $3.33B vs. $3.35B in 3Q21.Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95","news_type":1,"symbols_score_info":{"BMY":0.9}},"isVote":1,"tweetType":1,"viewCount":3125,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Bristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line<blockquote>百时美施贵宝非 GAAP 每股收益为 1.83 美元，超过预期为 0.03 美元，收入为 12B 美元</blockquote>

评论（1）

热议股票